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Positron emitting radionucUdes have unique properties that 
make them nearly ideal as radioactive tracers for in vivo 
metabolic studies. Using positron emission tomographic 
(PET) scanning and positron-labeled radiopharmaceuticals, 
one can study local glucose metabolism in dssues, blood 
Developments in radiopharmaceutical science, nuclear 
medicine imaging technology, and computer modeling of 
biological processes have led to techniques that now per-
mit the noninvasive measurement of basic physiologic pro-
cesses within the human body. Determination of blood flow 
in tissues, local glucose metabolism in tissues, utilization of 
oxygen, efficiency of oxygen extraction from blood, and mea-
surements of local receptor density and binding activity are 
all possible. The nuclear medicine techniques that make 
possible these determinations are designated the collective 
name of positron emission tomography (PET). 
Requirements for Functional Imaging 
To measure a physiologic process within the body (for ex-
ample, local glucose metabolism in tissues), it is necessary 
to have a tag or tracer for glucose that can be accurately 
followed through the metabolic process. The ideal tracer 
must not disturb the measured physiologic process, must be 
safe, and should be measurable from outside the body for 
in vivo studies. 
Commonly used positron radionuclides include positron 
emitting isotopes of carbon, oxygen, and nitrogen, which are 
the basic building-block atoms of organic molecules, and 
fluorine-18, which can be substituted for hydrogen in many 
organic molecules without significantly changing their bio-
physical behavior. These four radioisotopes provide positron 
emitting tags that can be synthesized into physiologically im-
portant substrates without altering the chemical or biophysi-
cal behavior of these substrates within the body. Thus, they 
meet the first criterion for an ideal tracer, not altering nor-
mal body biochemistry. 
The positron mode of radioactive decay is unique among 
the radioactive tracers currently used for nuclear medicine 
imaging. The positron emitted during such decay represents 
an electron with a positive charge. Such a particle, unable 
to exist in normal matter, promptly undergoes what is called 
an annihilation reaction with a normal (negatively charged) 
electron. To satisfy the requirement for conservation of 
energy, two gamma rays are emitted as a result of this 
flow, oxygen udlizadon, protein synthesis, and many ot/,e 
functions noninvasively in normal subjects and patients who 
have various diseases. A review of some of these techniques 
and the relative advantages and problems associated with 
the PET approach is presented. 
annihilation reaction. These gamma photons, which carry the 
energy equivalent of the rest-mass of two electrons, are given 
off in exactly 180° opposite directions from one another, pro. 
viding an ideal format for external detection and localiza-
tion. This pair of annihilation gamma rays are the means for 
easy, quantitative, noninvasive localization within the body, 
When considering the use of radioactive tracers, safety usual-, 
ly refers to limiting patient radiation from the tracer. Positron-1 
labeled tracers are usually safe for two reasons. First, because' 
of the extremely short physical half-life of most positron emit-
ters (Table) the radioactivity disappears from the body rapidly. 
Thus, total time of exposure is short, and the total integrated 
radiation dose is small. Second, because it is often possible 
to synthesize labeled compounds with high specific activi-
ties, only small amounts of labeled material must be admin-
istered to be detected. 
The 180° opposed pair of annihilation photons provides 
ideal geometry for external localization and quantification 
of radiotracers within the body. The key to accurate extemal 
tracer imaging has been the development of positron emis-
sion tomographs, so-called PET scanners. The fact that a pair 
of gamma rays traveling in exactly opposite directions is emit' 
ted with each annihilation event is used to determine exact-
ly the line along which the annihilation event occurred. 
Detectors placed on opposite sides ofthe body are directed 
toward each other and operated in what is known as the co-
incidence mode, wherein a radioactive decay event is no*! 
counted unless both detectors simultaneously detect a gam-
ma ray. A ring of such detectors surrounding the body si' 
multaneously measure the multiple lines of localization for 
many individual radioactive decay events. With this infor-
mation and computer technology, a computed tomograp'' 
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Table 
Position Emitting Radionuclides in Current Use 
Radionuclide 
Oxygen-15 
Carbon-11 
Nitrogen-13 
Fluorine-18 
Gallium-68 
Rubidium-81 
Rubidium-82 
Physical Half-Life (minutes) 
2.1 
20.4 
10.0 
110.0 
68.5 
274.8 
1.3 
ofthe distribution of radioactivity is calculated. The mathe-
matics are exactly the same as those used in X-ray computed 
tomography, but the resulting tomogram shows the distribu-
tion of radioactivity rather than X-ray density. Ifthe measure-
ments are made properly and certain correction factors are 
applied, the resulting computed tomogram is a quantitative-
ly accurate map of the distribution of radioactive tracer with-
in a volume section of the body. 
Modern PET scanners simultaneously produce multiple, con-
tiguous tomographic images. In effect, such multisection PET 
scanners provide a three-dimensional image ofthe distribu-
tion of radioactive tracer within a given part of the body. 
Thus, using an appropriately selected positron-labeled radio-
pharmaceutical and a modern, multisection PET scanner, 
maps are constructed of the distribution and time-course of 
the metabolism of physiologic substrates within the body. 
Finally, the use of positron technology to study in vivo pro-
cesses requires a computerized mathematical model of the 
metabolism of a given physiologic substrate. For example, 
the tracer i'*F-fluoro-2-deoxy-D-glucose (FDC) is a positron-
labeled analog of glucose. After intravenous administration 
ofthe tracer, its distribution within the body is related to the 
local rate of glucose metabolism by specific tissues. The ratio 
of the absolute tracer uptake of a specific tissue and the ac-
tual rate of glucose metabolism within that tissue is not one 
to one, however. Detailed knowledge of how the tracer is 
metabolized and localized within the tissue is necessary to 
evaluate results of the study. Knowledge of the exact pro-
cess permits construction of a mathematical model and a 
computer program that wil l convert the initial PET scan of 
FDC detected within the tissue into a map of local glucose 
metabolism. 
Currently, models are available for accurately measuring 
local tissue glucose metabolism rates (1,2), blood flow with-
in specific tissues (3-5), oxygen utilization within specific 
tissues (4,5), and the extraction fraction of oxygen from blood 
circulation through a given organ or area of an organ (4). 
^ great deal of work now underway is designed to measure 
'ocal tissue receptors for a variety of biochemical messen-
gers (6,7). Similarly, investigators are trying to develop ac-
curate models for parameters such as blood-brain barrier per-
'Tieability and local rates of protein synthesis (8). 
Applications of PET Scanning 
Every physiologic/metabolic process is potentially amenable 
"mvestigation using PET techniques, provided a suitable 
tracer can be synthesized in a short enough period of time. 
Methods for studying a large number of physiologic processes 
have already been developed and applied to many normal 
and pathologic conditions. A large percentage of PET re-
search has focused on normal and abnormal central nervous 
system (CNS) function. A few selected examples serve to in-
troduce the beauty and depth of these techniques. 
Cerebral glucose metabolism rate 
When administered intravenously, the tracer FDC enters the 
metabolized pool of glucose and is taken up by cells that 
are actively metabolizing glucose. Once within the cell, FDC 
is phosphorylated but cannot progress further in the meta-
bolic pathway for glucose. In essence, the labeled compound 
becomes trapped in the cell. By obtaining a PET scan after 
the administration of FDC, the local rate of glucose metab-
olism can be calculated using an appropriate computer 
model, and the result can be presented as a functional im-
age, a quantitative map of the rate of glucose metabolism 
in the tissue (1). 
Figure 1 is an example of such a functional image of glu-
cose metabolism in the normal human brain. Images are 
shown at four levels. The darker the area, the greater the local 
0% 
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Fig 1 
Computer processed functional images depicting glucose metabolic rate 
in healthy 26-year-old male volunteer. Scale is in mg of glucose metabolized 
per minute per 100 g of tissue. Sections are contiguous; A = lowest, 
D = highest. (Courtesy of University of Michigan.) 
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Fig 2 
Images of glucose metabolism rate in four patients with left middle cerebral 
artery infarct (A), Huntington's chorea (B), left temporoparietal glioma 
(O, and left temporal lobe epilepsy (D). (Courtesy of University of Michigan.) 
metabolic rate. Note the clear localization of glucose metab-
olism in the cerebral gray matter, the basal ganglia, and the 
thalamus; much lower rates of glucose utilization are seen 
within white matter. 
Figure 2 shows representative sections of four patients who 
have, respectively, a left hemispheric stroke, Huntington's 
chorea, a large glioma, and left temporal lobe epilepsy. Note 
the decreased glucose utilization within the area of infarct, 
disclosing the tissue injury and loss of function within this 
area. In the patient who has Huntington's chorea, the study 
demonstrated a striking loss of glucose in the area of the cau-
date nuclei (compare with Fig 1), concordant with the ana-
tomic abnormality found in such patients. 
In addition to many studies of various CNS diseases (2-4, 
9-14), PET scanning has been used extensively to study nor-
mal CNS function (2,5,15). Striking alterations in regional 
glucose utilization in the brain occur with various normal 
physiologic functions such as listening, memorizing, and see-
ing (15,16). For example, Mazziotta and coworkers (15) 
demonstrated changes in lateralization of function related 
to hearing that depended on whether the individual was lis-
tening to music or speech. 
Cerebral blood flow 
A number of methods have been developed to measure cere, 
bral blood flow using PET methods (3-5). Figure 3 is a repre. 
sentative example of a functional map of cerebral blood flow 
in a normal individual. The tracer was oxygen-15 labeled 
water. As expected in this normal subject, the local cerebral 
blood flow rather closely paralleled the local cerebral meta-
bolic rate for glucose (Fig 1). This parallelism does not exist 
in many disease states; physiologic/metabolic imbalances 
have been documented in such states as acute stroke, luxury-
perfusion syndrome, misery-perfusion syndrome, and 
neoplasm (3,4). 
Other applications 
Much excellent work relating PET methods to heart and myo-
cardial metabolism has been accomplished. Because the 
heart normally uses free fatty acids as a primary substrate 
for energy metabolism, carbon-11 labeled palmitic acid is 
an excellent tracer for determination of myocardial metabo-
lism. Schon et al produced functional images of local myo-
cardial fatty acid metabolic rate and have studied a wide 
variety of cardiac conditions with this technique (17). 
Problems and Predictions 
The ability to make such elegant measurements of various 
Fig 3 
Functional image of cerebral blood flow in normal subject. Calculated 
"O-HjO method. (Courtesy of University of Michigan.) 
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hysiologic processes within the body is bought at a price, 
however. The physical half-life ofthe various positron emit-
jipg radioisotopes is quite short (Table). Fluorine-18, for ex-
ampIS' has a physical half-life of less than two hours, and 
oxygen-'iS, a half-life of only two minutes. Elaborate and 
fechnologically complex solutions are required in order to 
jse tracers that have such an evanescent existence. Typical-
ly a fully equipped radiosynthetic chemistry laboratory is 
needed immediately adjacent to the scanning site. Most posi-
tron emitting radionuclides are produced using cyclotrons 
thatare small enough to be installed and operated physically 
close to a medical research facility. A large number of posi-
tron research sites developed around the world in recent 
years have on-site cyclotrons for the local, immediate pro-
duction ofthe tracer radioisotopes that they use. However, 
in their present state of development, these machines are not 
suitable for routine clinical production of radionuclides. 
Metabolic research using positron-labeled radiotracers 
requires a relatively elaborate and technically complex 
underpinning. An on-site cyclotron, a specially tailored radio-
chemistry and radiopharmaceutical synthetic facility, a PET 
scanner, and relatively sophisticated computing and image 
processing facilities are all necessary to conduct such re-
search successfully. Work is currently underway in many 
centers to simplify, miniaturize, and automate many ofthese 
procedures; it may be possible in the future to incorporate 
positron technology into general patient care, at least at large 
tertiary care centers. For the present, this approach to medical 
imaging and physiologic research remains a highly special-
ized, albeit extremely elegant and productive, means of 
examining the human body. 
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